Abstract
To elucidate the differences in pathogenesis between lymphoma-associated hemophagocytic syndromes (LAHS) of theT-cell/ natural killer cell (T/NK) and B-cell (B) types,we comparatively analyzed the clinical features and serum cytokine profiles of 33 patients with LAHS registered in the Kyoto University Hematology/Oncology Study Group.The serum cytokine levels of each patient group (B-LAHS versusT/NK-LAHS) were expressed as the ratio of the median to the upper normal values of the respective cytokines and were as follows: 19.05 versus 13.99 for soluble interleukin 2 (IL-2) receptor, 0.67 versus 0.67 for granulocytemacrophage colony-stimulating factor (GM-CSF), 0.64 versus 1.26 for G-CSF, 5.70 versus 3.61 for M-CSF, 1.54 versus 3.39 for interferon γ (IFN-γ), 13.17 versus 1.17 for IL-6, 6.88 versus 1.58 for tumor necrosis factor α (TNF-α), 0.71 versus 0.41 for IL-1, 1.99 versus 0.21 for IL-12, and 105.32 versus 29.65 for IL-10.The serum levels of IL-6,TNF-α, and IL-10 were significantly higher in the B-LAHS group,whereas those of IFN-γ were significantly lower. These differences between the 2 groups may reflect a difference in the pathogenesis. Higher serum levels of IL-6, TNF-α, and IL-10 may be derived at least partly from neoplastic B-cells themselves. In addition, the extremely high serum levels of IL-10 suggest that a compensatory anti-inflammatory process may operate in both groups and give rise to a profound immunosuppressive state and a poor outcome.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Wong KF, Chan JK. Reactive hemophagocytic syndrome: a clinicopathologic study of 40 patients in an Oriental population.Am J Med. 1992;93:177–180.
Imashuku S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment.Int J Hematol. 1997;66:135–151.
Komp DM, McNamara J, Buckley P. Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes.Blood. 1989;73:2128–2132.
Ishii E, Ohga S, Aoki T, et al. Prognosis of children with virus-associated hemophagocytic syndrome and malignant histiocytosis: correlation with levels of serum interleukin-1 and tumor necrosis factor.Acta Haematol. 1991;85:93–99.
Imashuku S, Ikushima S, Esumi N, Todo S, Saito M. Serum levels of interferon-gamma, cytotoxic factor and soluble interleukin-2 receptor in childhood hemophagocytic syndromes.Leuk Lymphoma. 1991;3:287–292.
Fujiwara F, Hibi S, Imashuku S. Hypercytokinemia in hemophagocytic syndrome.Am J Pediatr Hematol Oncol. 1993;15:92–98.
Akashi K, Hayashi S, Gondo H, et al. Involvement of interferon- and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults.Br J Haematol. 1994;87:243–250.
Imashuku S, Hibi S, Fujiwara F, Ikushima S, Todo S. Haemophagocytic lymphohistiocytosis, interferon-gamma-naemia and Epstein- Barr virus involvement.Br J Haematol. 1994;88:656–658.
Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.J Clin Oncol. 1995;13:575–582.
Imashuku S, Hibi S, Fujiwara F, Toda S. Hyper-interleukin (IL)-6- naemia in haemophagocytic lymphohistiocytosis.Br J Haematol. 1996;93:803–807.
Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis.Blood. 1997;89:4100–4103.
Takada H, Ohga S, Mizuno Y, et al. Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity.Br J Haematol. 1999;106:182–189.
Takeshita M, Kikuchi M, Ohshima K, et al. Bone marrow findings in malignant histiocytosis and/or malignant lymphoma with concurrent hemophagocytic syndrome.Leuk Lymphoma. 1993;12:79–899.
Yao M, Cheng AL, Su IJ, et al. Clinicopathological spectrum of hemophagocytic syndrome in Epstein-Barr virus-associated peripheral T cell lymphoma.Br J Haematol. 1994;87:535–543.
Wilson MS, Weiss LM, Gatter KC, Mason DY, Dorfman RF, Warnke RA. Malignant histiocytosis: a reassessment of cases previously reported in 1975 based on paraffin section immunophenotyping studies.Cancer. 1990;66:530–536.
Reiner AP, Spivak JL. Hematophagic histiocytosis: a report of 23 new patients and a review of the literature.Medicine. 1988;67:369–3888.
Falini B, Pileri S, De Solas I, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome.Blood. 1990;75:434–444.
Cheng AL, Su IJ, Chen YC, Uen WC, Wang CH. Characteristic clinicopathological features of Epstein-Barr virus-associated peripheral T-cell lymphoma.Cancer. 1993;72:909–916.
Chang CS, Wang CH, Su IJ, Chen YC, Shen MC. Hematophagic histiocytosis: a clinicopathologic analysis of 23 cases with special reference to the association with peripheral T-cell lymphoma.J Formos Med Assoc. 1994;93:421–428.
Su IJ, Wang CH, Cheng AL, Chen RL. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management.Leuk Lymphoma. 1995;19:401–406.
Wong KF, Chan JKC, Lo ESF, Wong CSC. A study of the possible etiologic association of Epstein-Barr virus with reactive hemophagocytic syndrome in Hong Kong Chinese.Hum Pathol. 1996;27:1239–12422.
Kuratsune H, Machii T, Aozaka K, et al. B cell lymphoma showing clinicopathological features of malignant histiocytosis.Acta Haematol. 1988;79:94–98.
Nakamoto T, Ogawa S, Mano H, Hirai H, Yazaki Y. Hemophagocytic syndrome associated with non-Hodgkin’s lymphoma of B-cell type.Am J Hematol. 1994;47:335–336.
Murase T, Nakamura S, Tashiro K, et al. Malignant histiocytosislike B-cell lymphoma, a distinct variant of intravascular lymphomatosis: a report of five cases and review of the literature.Br J Haematol. 1997;99:656–664.
Ohno T, Miyake N, Hada S, et al. Hemophagocytic syndrome in five patients with Epstein-Barr virus-negative B-cell lymphoma.Cancer. 1998;82:1963–1972.
Takahashi T, Kanda Y, Mori M, et al. B-cell lymphoma-associated hemophagocytic syndrome after PBSCT.Bone Marrow Transplant. 1998;21:623–625.
Shimazaki C, Inaba T, Shimura K, et al. B-cell lymphoma associated with haemophagocytic syndrome: a clinical, immunological and cytogenetic study.Br J Haematol. 1999;104:672–679.
Takahashi N, Chubati A, Miura I, Nakamura S, Miura T. Lymphoma- associated hemophagocytic syndrome in Japan [in Japanese, abstract in English].Jpn J Clin Hematol. 1999;40:542–549.
Miyahara M, Sano M, Shibata K, et al. B-cell lymphoma-associated hemophagocytic syndrome: clinicopathological characteristics.Ann Hematol. 2000;79:378–388.
Allory Y, Challine D, Haioun C, et al. Bone marrow involvement in lymphomas with hemophagocytic syndrome at presentation: a clinicopathologic study of 11 patients in a Western institution.Am J Surg Pathol. 2001;25:865–874.
Su IJ, Hsieh HC, Lin KH, et al. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis.Blood. 1991;77:799–808.
Craig FE, Clare CN, Sklar JL, Banks PM. T-cell lymphoma and the virus-associated hemophagocytic syndrome.Am J Clin Pathol. 1992;97:189–194.
Kikuta H, Sakiyama Y, Matsumoto S, et al. Fatal Epstein-Barr virus-associated hemophagocytic syndrome.Blood. 1993;82:3259–32644.
Kawaguchi H, Miyashita T, Herbst H, et al. Epstein-Barr virusinfected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome.J Clin Invest. 1993;92:1444–1450.
Su IJ, Hsu YH, Lin MT, Cheng AL, Wang CH, Weiss LM. Epstein- Barr virus-containing T-cell lymphoma presents with hemophagocytic syndrome mimicking malignant histiocytosis.Cancer. 1993;72:2019–20277.
Dolezal MV, Kamel OW, van de Rijin M, Cleary ML, Sibley RK, Warnke RA. Virus-associated hemophagocytic syndrome characterized by clonal Epstein-Barr virus genome.Am J Clin Pathol. 1995;103:189–194.
Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ. Upregulation of tumor necrosis factor-gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome.J Clin Invest. 1997;100:1969–19799.
Ohshima K, Haraoka S, Harada N, et al. Hepatosplenic gamma delta T-cell lymphoma: relation to Epstein-Barr virus and activated cytotoxic molecules.Histopathology. 2000;36:127–135.
Ohno T, Kanoh T, Arita Y, et al. Fulminant clonal expansion of large granular lymphocytes: characterization of their morphology, phenotype, genotype, and function.Cancer. 1988;62:1918–1927.
Kawa-Ha K, Ishihara S, Ninomiya T, et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein- Barr viral DNA.J Clin Invest. 1989;84:51–55.
Watari K, Asano S, Shirafuji N, et al. Serum granulocyte colonystimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay.Blood. 1989;73:117–122.
Heaney ML, Dolde DW. Soluble cytokine receptors.Blood. 1996; 87:847–857.
Luoghnan MS, Sanderson CJ, Nossal GJV. Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5.Proc Natl Acad Sci U S A. 1988;85:3115–3119.
de Totero D, di Celle PF, Cignetti A, Foa R. The IL-2 receptor complex: expression and function on normal and leukemic B cells.Leukemia. 1995;9:1425–1431.
Imashuku S, Hibi S, Tabata Y, Todo S. Hemophagocytic syndrome in five patients with Epstein-Barr virus-negative B-cell lymphoma.Cancer. 1999;85:2298–2300.
Abken H, Fluck J, Willecke J. Four cell-secreted cytokines act synergistically to maintain long term proliferation of human B cell lines in vitro.J Immunol. 1992;149:2785–2794.
Boussiotis VA, Nadler LM, Strominger JL, Goldfeld E. Tumor necrosis factor is an autocrine growth factor for normal human B cells.Proc Natl Acad Sci U S A. 1994;91:7007–7011.
Genestier L, Bonnefoy-Berard N, Rouault JP, Flacher M, Revillard JP. Tumor necrosis factor-up-regulates Bcl-2 expression and decreases calcium-dependent apoptosis in human B cell lines.Int Immunol. 1995;7:533–540.
Kato H, Kinoshita T, Suzuki S, et al. Elevated serum interleukin-6 (IL-6) is derived from neoplastic lymphoid cells in patients with Bcell non-Hodgkin’s lymphoma: correlation with extent of IL-6 expression and serum concentration.Br J Haematol. 1996;92:1014–10211.
Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors.Cancer Res. 1996;56:5499–5505.
Benjamin D, Park CD, Sharma V. Human B cell interleukin 10.Leuk Lymphoma. 1994;12:205–210.
Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin’s lymphoma.Leuk Lymphoma. 1997;26:251–259.
Khatri VP, Caligiuri MA. A review of the association between interleukin-10 and human B-cell malignancies.Cancer Immunol Immunother. 1998;46:239–244.
Ip M, Chan KW, Chan IKL. Systemic inflammatory response syndrome in intravascular lymphomatosis.Intensive Care Med. 1997; 23:783–786.
Deusch E, Mayer A, Hobisch-Hagen P, et al. Angiotropic large Bcell lymphoma misdiagnosed as urosepsis with multiple organ dysfunction syndrome.Acta Anaesthesiol Scand. 1999;43:100–103.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.Crit Care Med. 1992;20:864–874.
Romagnani S. Cytokines and the Th1/Th2 paradigm. In: Balkwill F, ed. The Cytokine Network and Immune Functions. Oxford, UK: Oxford University Press; 2000:73–93.
Kallio R, Surcel HM, Bloigu A, Syrjala A. Balance between interleukin- 10 and interleukin-12 in adult cancer patients with or without infections.Eur J Cancer. 2001;37:857–861.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ohno, T., Ueda, Y., Nagai, Ki. et al. The Serum Cytokine Profiles of Lymphoma-associated Hemophagocytic Syndrome: A Comparative Analysis of B-Cell and T-Cell/Natural Killer Cell Lymphomas. Int J Hematol 77, 286–294 (2003). https://doi.org/10.1007/BF02983788
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02983788